Frontlight ResearchEarly access
CompletedNo phase
Preoperative Prophylactic Fosfomycin Trometamol Versus 5-day Levofloxacin in Prevention of Postpercutaneous Nephrolithotomy Infectious Complications and Sepsis.
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 210 people enrolled
- Started
- 1 Jan 2023
- Ended
- 1 Jan 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- PCNL
- Record updated
- 21 January 2026
Who can take part
- Age
- 15 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- adult patients with renal stones scheduled for PCNL
Who cannot take part
- Unfit patients for surgery
- patients with active UT
- uncorrected coagulopathy
- pregnancy
- children
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A randomized controlled trial comparing the use of preoperative prophylactic single dose fosfomycin trometamol versus levofloxacin in prevention of post-PCNL infectious complications and sepsis.
Read full original descriptionShow less
the 3 groups were compared as regards the baseline data, preoperative data, intra-operative data, and post-op data.
The 3 groups in the trial
- Preoperative Fosfomycin Trometamol groupExisting treatment, for comparison
Fosfomycin before PCNL
Treatment: PCNL
- Preoperative 5-day Levofloxacin groupExisting treatment, for comparison
Levofloxacin before PCNL
Treatment: PCNL
- No preopertive antibiotic groupOther group
control, no preoperative antibiotic before PCNL
Treatment: PCNL
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Preoperative Prophylactic Single Dose Fosfomycin Trometamol Versus 5-day Levofloxacin in Prevention of Post-percutaneous Nephrolithotomy Infectious Complications and Sepsis: A Prospective Randomized Controlled Trial.
- Record updated
- 21 January 2026